MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis

Table 1

Biological and clinicopathological features of CLL patients.

Total number of patients	88
Patients’ sex (male/female)	62/26
	Median (range)
Age (years)	70 (50–90)
OS (months)	42 (4–120)
White blood cells (×10^6/mL)	32,250 (8500–96,900)
Lymphocytes (×10^6/mL)	23,050 (5300–69,430)
CD38 expression (mean optical intensity of staining)	7.7 (0.10–59.2)
Early apoptosis index (55/88 patients)	4.7 (0.01–54.8)
	Number of patients (%)
Binet stage
A	50 (56.8%)
B	16 (18.2%)
C	22 (25.0%)
Rai stage
0	16 (18.2%)
I	27 (30.7%)
II	24 (27.3%)
III	4 (4.5%)
IV	17 (19.3%)
Risk group
Low	16 (18.2%)
Intermediate	51 (58.0%)
High	21 (23.9%)
Serum LDH concentration
Normal	60 (68.2%)
Elevated	28 (31.8%)
CD38 expression status
Negative	73 (83.0%)
Positive	15 (17.0%)
IGHV mutational status
Mutated	45 (51.1%)
Unmutated	43 (48.9%)

CLL: chronic lymphocytic leukemia; OS: overall survival; LDH: lactate dehydrogenase; IGHV: immunoglobulin heavy chain variable region.